By targeting both receptors in a bispecific manner, the activity of the bsAb is not only directed to the tumor side, eventually introducing anti-tumor responses, but also may result in a more favorable safety profile and better efficacy compared to standard anti-CTLA4 mAbs (88, 96). The gene discussed is CTLA4; the disease is neoplasm.